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SUMMARY
1. Chronic pain owing to arthritis is a major clinical problem
worldwide. To study the underlying pathological mechanisms
of chronic pain and the effectiveness of different treatments,
a number of experimental models have been developed over the
years.
2. We introduced a new subchronic inflammatory model by
repeated unilateral administration of carrageenan into the ankle
joint of rats, and investigated the degree and the time-course of
the oedema, and thermal and mechanical hyperalgesia.
3. Carrageenan (450 mg) was injected on three occasions (on
days 1, 4 and 7), and the resulting oedema, thermal hyperalgesia
(paw withdrawal test) and weight load were characterized in
voluntarily walking rats daily for 15 days. The effect of diclofenac
sodium (3 mg/kg orally daily for 15 days) was also determined.
4. Repetitive administration of carrageenan caused fluctuat-
ing oedema and pain responses, which did not normalize within
3 days. Exacerbated inflammatory oedema was observed after
the second and third injections. Oedema and a decreased weight
load of the inflamed paw were observed throughout the investi-
gation period, and paw withdrawal thresholds to noxious
thermal stimuli returned to baseline pre-carrageenan values
from Day 13.
5. Oral diclofenac (3 mg/kg daily for 15 days) significantly
decreased oedema within a few days (Day 3), whereas its anti-
allodynic effect developed only several days later (Day 9). How-
ever, diclofenac at the applied dose did not influence the thermal
hyperalgesia.
6. The results suggest that the repeated administration of
carrageenan might be a suitable model for determining the
effects of long-lasting treatment.
Key words: arthritis, chronic pain model, diclofenac, gait
analysis, hyperalgesia, oedema.
INTRODUCTION
Chronic pain owing to arthritis is a major clinical problem world-
wide. To study the underlying pathological mechanisms of chronic
pain and the effectiveness of different treatments, a number of experi-
mental models have been developed over the years. One of the most
common animal models of arthritis is the inflammation induced
by complete Freud’s adjuvant (CFA) (heat-killed Mycobacterium
butyricum). Systemic injection of CFA induces long-lasting inflam-
mation in multiple joints, resulting in severe conditions in which
polyarthritis is accompanied by widespread systemic disease, com-
plicating the interpretation of the data.1 To our knowledge, very few
models of mono-arthritis have been described yet. The most widely
used method for mono-arthritis induction is the local administration
of CFA in low doses. However, an increase in the circumference of
the joint develops after several days (around Day 3), and it cannot
be determined whether systemic inflammation occurs in some
animals.2 The injection of CFA into the tibiotarsal joint gives rise
to intensive and persistent mechanical and thermal hyperalgesia
with duration of over 4 weeks, supposing that it causes long-lasting
suffering.3 Therefore, despite the advantages of this model, the severe
pain associated with the disease provokes ethical concern, which has
prompted several workers to develop other models of mono-arthritis.
Furthermore, it is well known that the course of rheumatoid arthritis
is intermittent, therefore a model with a consistent pattern would
be more advantageous. Carrageenan is a frequently used agent for
the induction of experimental inflammation and inflammatory pain,
which is considered relevant to clinically important inflammatory
pain states. In some studies, researchers have applied two carrageenan
injections into the plantar surface 7 days apart,4,5 and investigated
the pain and inflammation of the paw, finding that the rats recovered
completely. Only one article has reported on injections of carra-
geenan repeated twice within a shorter interval (72 h) into the knee
joint (300 mg) on the mechanical nociceptive sensitivity in rats.6
These studies suggest that repeated application of carrageenan might
be a valuable model for chronic/subchronic inflammation.
The main purpose of the present study was to characterize the extent
of subchronic single-joint inflammation induced by repeatedly injected
carrageenan. The second goal was to investigate whether a recently
introduced device (developed to characterize the weight load in
voluntarily walking rats) is a reliable method for the determination
of pain sensation after ankle joint inflammation. Finally, we also tested
the anti-inflammatory and antinociceptive effects of diclofenac, which
is a well-known non-steroidal anti-inflammatory drug (NSAID).
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METHODS
After institutional ethical approval had been obtained (Institutional Animal
Care Committee of the Faculty of Medicine, University of Szeged), male
Wistar rats (Charles River strain; Bioplan, Budapest, Hungary) were housed
in groups of five or six animals per cage, with free access to food and water,
and keeping to the natural light : dark cycle.
The following drugs were administered: g-carrageenan (Sigma-Aldrich
Kft., Budapest, Hungary) dissolved in physiological saline and diclofenac
sodium (Voltaren 75 mg/3 mL injection; Novartis Hungária Kft., Budapest,
Hungary). Diclofenac sodium was administered orally daily for 15 days
through a gastric tube (3 mg/kg per day; 2 mL/kg volume, diluted with saline).
This dose has significant anti-inflammatory potency in rats.7,8 The control
group received the same volume of physiological saline. The first injection
was applied 3 h after the carrageenan injection.
To induce arthritis, g-carrageenan (450 mg/30 mL) was injected into the
tibiotarsal joint cavity of the right hind leg on days 1, 4 and 7. All treatments
were given to gently restrained conscious animals, using a 27-gauge needle,
and without anaesthesia so as to exclude any drug interaction. These injections
did not elicit any signs of major distress, such as audible vocalizations or
attempts to bite the experimenter.
The rats were randomly assigned to the control and treatment groups,
and all of the entered rats completed the study (Table 1).
To follow the changes in the size of the inflamed joint, we measured the
antero-posterior and medio-lateral aspects of the ankle joint with an electronic
calliper. The cross-section area was calculated by the formula a ¥ b ¥ p,
where a and b are the radius in the two aspects.
Two types of nociceptive tests were performed. In the first series of experi-
ments, thermal hyperalgesia was assessed by means of the paw withdrawal
(PWD) test; and in the second, weight load test was used to measure mechanical
hyperalgesia. The two tests were performed in different animals to decrease
the level of stress and pain stimuli, which might have influenced the results.
In the PWD test, the rats were placed on a glass surface in a plastic chamber
and allowed to acclimatize to their environment for 20 min before the hind
paw withdrawal latencies were determined. Heat stimulus was directed onto
the plantar surface of each hind paw. Cut-off time was set at 20 s to avoid
tissue damage. A detailed description of this method has been published else-
where.9 The weight load test on each leg was performed according to a model
introduced recently by Min et al.10 The apparatus consists of a starting box,
a path and an arrival box. The path of the apparatus is constructed in such
a way that while a rat is walking through it, the weight load on a given leg
of the animal can be monitored at a maximum of four different spots
along the path. The output of each load cell is fed to a digital amplifier for
appropriate amplification and filtering. The processed signal is sent to a
personal computer and plotted as a time-course curve. The rats were trained
in the apparatus for three days before the first carrageenan injection was
administered. The test was repeated three times consecutively each day. Both
pieces of equipment were homemade as the cited authors suggested.
The PWD latencies or the weight load and the diameters were obtained
consecutively on days 1, 4 and 7 in the morning (am) before and again 3 h
after (pm) the carrageenan injections. On the other days, the measurements
were made once daily in the afternoon for 15 days. Throughout the study,
the measurements were carried out in a double-blind fashion.
Data are presented as the mean±SEM. As the weight applied to the one
leg depends on the bodyweight, the weight load value was expressed as a
percentage of bodyweight (relative weight load; RWL).
Analysis of variance (anova) of the data for repeated measures was
used to examine for any overall effects, followed by the Fisher LSD test.
A probability level of 0.05 was considered significant.
RESULTS
There were no significant differences in weight between the groups
on days 1 and 15, and the weights of the animals increased similarly
and significantly in each group during the 2 weeks (Table 1), suggest-
ing that diclofenac did not cause severe gastric toxicity. Similarly,
the basal values of the different parameters (i.e. weight load, PWD
latency and ankle cross-section area) did not differ significantly
between the control and the diclofenac-treated groups (Tables 1,2);
accordingly, we did not normalize the data to the weight of the animals,
except for the weight load (RWL).
Oedema
The first injection of carrageenan caused a similar degree of oedema
in all groups on the inflamed side 3 h after the injection, but it did
not influence the cross-section area on the contralateral side (Table 1).
As there were no significant differences between the two control and
two diclofenac-treated groups at any time throughout the period,
we merged these data for further analysis.
With regard to the changes in time in the control group, we found
that the oedema was maximal 3 h and 24 h after the first carrageenan
injection; it decreased significantly on days 3 and 4, but did not
normalize. The second carrageenan injection caused a higher degree
of oedema on days 4, 5 and 6; that is, the cross-section was signific-
antly larger when compared with that on days 1, 2 and 3, respectively
(Fig. 1). The third carrageenan injection caused a similar degree
of oedema as that by the second application. The oedema decreased
continuously from Day 9, but significant differences could be observed
between the two sides throughout the period. No significant changes
were observed on the normal side.
Considering the diclofenac-treated group, the second and third
injections of carrageenan did not cause an increased level of oedema,
but significant differences were observed between the two sides
during the whole period. The comparison revealed that there were
Table 1 Treatment schedule. Bodyweight and baseline values of the ankle cross-section area on Day 1 before and 3 h after carrageenan injection
Group n Nociceptive 
test
Oedema 
test
Weight (g) Ankle cross-section area (mm2) 
Pre-carragenan Post-carrageenan
Day 1 Day 1 Day 15 Day 15 Right Left Right Left
Control 7 PWD + 254 ± 7.5 257 ± 5.2 312 ± 7.7 314 ± 5.7 47 ± 2.5 47 ± 2.0 95 ± 3.1* 46 ± 2.3
Control 6 Weight load (g) + 262 ± 7.3 316 ± 9.1 52 ± 0.7 52 ± 1.3 97 ± 3.1* 51 ± 1.7
Diclofenac 9 PWD + 267 ± 13.6 262 ± 8.5 341 ± 9.0 330 ± 6.9 50 ± 2.2 51 ± 2.2 94 ± 5.3* 51 ± 1.4
Diclofenac 6 Weight load (g) + 254 ± 6.6 312 ± 6.2 53 ± 1.4 50 ± 1.5 94 ± 1.2* 49 ± 0.5
*Significantly different compared with the pre-carrageenan value (P < 0.05).
PWD, paw withdrawal; n, number of animals.
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significant differences between the two groups from Day 3; that is,
the ankle cross-section area was significantly larger in the control
group than in the diclofenac-treated group. There were no significant
differences between the groups on the normal side.
Paw withdrawal test
All three g-carrageenan injections significantly decreased the PWD
latency on the inflamed side in both groups, whereas the thermal
sensitivity of the unaffected paw did not alter significantly through-
out the experiment (Table 2; Fig. 2). There were no significant
differences in the hyperalgesic effects between the first, second and
third injections of carrageenan. Paw withdrawal latency increased
from days 2 to 4 and days 5 to 6 and continuously from Day 8. There
were no significant differences between the two sides on the
mornings of days 6 and 7 and from Day 13 until the end. In terms
of diclofenac treatment, the changes were similar to those in the
control group; that is, there were no significant differences between
the two groups at any time points (Fig. 2).
Weight load test
Baseline weight load values were similar for both hind paws, but
the load borne by the fore paws was significantly less than that borne
by the hind paws (Table 2). Carrageenan injections resulted in a
significant reduction of RWL for the injected leg after 3 h, and the
decreased RWL persisted throughout the investigation period in
the control group, although its degree fluctuated (Fig. 3). The most
intensive RWL decrease was observed 1 day after the injections;
there was then a continuous improvement in the days that followed.
The repetition of carrageenan administration did not produce more
aggravated motor impairment.
Regarding the control left (non-inflamed) hind paw, an increase
in the RWL was observed from days 1 to 5. The RWL of the right
fore paw decreased significantly from Day 2 and persisted until
Day 12, and the load of the left fore paw was significantly increased
only 3 h after the first carrageenan injection.
The effect of diclofenac on the RWL on the inflamed side was
expressed slowly; that is, significant differences between the two
Fig. 1 Ankle cross-section area (mm2)
of the inflamed (I) and non-inflamed
(NI) hind paws of the control and
diclofenac-treated (3 mg/kg per day
orally for 15 days) animals. (), Control
I; (), control NI; (), diclofenac I;
and (), diclofenac NI. *Significantly
higher cross-section area compared
with the first carrageenan injection
value (P < 0.05). †Significant differences
between control and diclofenac-treated
animals (P < 0.05). #Significantly
different compared with carrageenan
values measured 3 h after the injection
(P < 0.05). The arrows show the time
points at which carrageenan was
injected.
Table 2 Baseline paw withdrawal (PWD) latencies and weight load on Day 1 before and 3 h after carrageenan injection
Group n Parameters Pre-carrageenan Post-carrageenan
Right FP Left FP Right HP Left HP Right FP Left FP Right HP Left HP
Control 7 PWD latency (s) 9.4 ± 0.59 10.3 ± 0.65  3.6 ± 0.60† 11.1 ± 0.77
Control 6 Weight load (g) 109.6 ± 4.18* 111.5 ± 3.19* 137.8 ± 3.70 135.2 ± 2.35 101.0 ± 6.42 128.5 ± 5.07† 100.4 ± 8.23† 160.2 ± 3.85†
Diclofenac 9 PWD latency (s) 9.8 ± 0.76 9.3 ± 0.50  4.1 ± 0.63† 10.8 ± 0.69
Diclofenac 6 Weight load (g) 114.9 ± 3.13* 104.0 ± 2.20* 138.6 ± 4.82 140.4 ± 4.47 102.3 ± 7.31 122.1 ± 4.02†  86.6 ± 7.35† 162.1 ± 3.32†
*Significantly different from the hind paw (P < 0.05).
†Significantly different from the pre-carrageenan value (P < 0.05).
FP, fore paw; HP, hind paw; n, number of animals.
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groups were observed only from Day 9, and the mechanical hyper-
algesia was relieved from Day 13, suggesting a faster recovery.
For the other paws, there were no significant differences between the
two groups. By contrast, in the diclofenac-treated groups we did not
observe the reciprocal changes in the RWL on the contralateral side.
DISCUSSION
The present data show that the repeated administration of carra-
geenan into the right ankle joint (450 mg on days 1, 4 and 7) caused
fluctuating oedema, and thermal and mechanical hyperalgesia.
The degree of oedema was exacerbated after the second and third
injections, but the thermal and mechanical hyperalgesia did not
change. The signs of inflammation gradually decreased after the last
carrageenan injection, thus the reduction in oedema and thermal
hyperalgesia began on the second day after the injections, but the
gait impairment was more persistent. Orally administered diclofenac
sodium resulted in a significant decrease in oedema within a few
(i.e. three) days, whereas its anti-allodynic effect developed only
several days later (Day 9). However, diclofenac treatment at the
applied dosage did not influence thermal hyperalgesia.
More than 10 years ago, Guilbaud et al. demonstrated that the first
inflammation enhances the pain behaviour (but not the oedema)
relative to a second inflammation induced in either the ipsilateral
or the contralateral hind paw.4,5 We found the opposite result in our
model; that is, we observed exacerbated oedema, but not increased
thermal and mechanical hyperalgesia. The reason for the inconsist-
ent results could be because of the difference in the interval between
injections after total recovery (which was 3 days apart in the present
study) compared with 7 days apart.5 Another explanation might be
the difference in the route of carrageenan injection (intraplantar vs
intra-articular), as it is well known that the mechanisms of pain
induced in the various tissue types (e.g. muscle, joint and skin) are
different.11,12 Thus, the central projections of the primary afferents
innervating muscles and joints are predominantly directed to lamina
I and deeper laminas of the dorsal horn, whereas those of the
cutaneous tissues also project to lamina II.13
Single administration of carrageenan into a joint is a well-known
inflammatory model in rats.11,14,15 A recent study investigated the
long-term effects of 300, 1000 or 3000 mg carrageenan injected into
the knee joint of rats,12 and the hyperalgesia in response to mechan-
ical and thermal stimuli was assessed at various time points for
8 weeks. The highest dose of carrageenan produced hyperalgesia
ipsilaterally and lasted for 7–8 weeks; however, it spread to the
contralateral side 1–2 weeks after the injection. A dose of 1000 mg
carrageenan produced a shorter-lasting hyperalgesia that remained
ipsilateral. A dose of 300 mg carrageenan caused only a short-lasting
(24 h) hyperalgesia. Thus, the degree and the duration of oedema
and pain was dependent upon the dose applied. As the carrageenan
was injected into the knee joint and the pain stimuli were applied
to the plantar surface of the hind paws, we determined secondary
thermal and mechanical hyperalgesia. The degree of hyperalgesia
seemed to be high, suggesting that higher doses of carrageenan
induced very severe and long-lasting pain in the animals. In the
present study, we also determined the level of secondary thermal
hyperalgesia (stimulus onto the plantar surface of the hind paw vs
pain induction in the joint) and found that decreases in the paw
withdrawal latencies of only about 2–3 s were observed 2 days after
the carrageenan injections, suggesting a lower level of suffering.
This is also supported by the observation that there was normal
weight gain (Table 1) and the animals walked voluntarily.
In terms of the inflammatory potential of CFA, Stein et al. inves-
tigated its nociceptive effect after unilateral intraplantar injection.16
The main difference when compared with our model was that the
inflammation was apparent within 12 h; it increased progressively,
reached a peak at Day 16 and then slowly subsided. The inflammation
Fig. 2 The time-response curves
indicate the paw withdrawal (PWD)
latencies on the inflamed (I) and non-
inflamed (NI) hind paws of the control
and diclofenac-treated animals. (),
Control I; (), control NI; (),
diclofenac I; and (), diclofenac NI.
The symbols denote a significant
(P < 0.05) difference between the
inflamed and non-inflamed sides of
the control (*) and diclofenac-treated
( †) groups. The arrows show the time
points at which carrageenan was
injected.
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spread to the contralateral hind paw in 10% of the animals. Further-
more, the animals also displayed a loss of bodyweight and a persistent
flexion of the knee joint. All of these signs suggest that Freund’s
adjuvant caused more massive inflammation and pain.
Several reports have demonstrated the histomorphometric changes
after repeated carrageenan injection into a joint,17,18 but only Daher
and colleagues assessed the influence of repeated injections of car-
rageenan (72 h apart; 300 mg) into the knee joint on the mechanical
nociceptive sensitivity by determining the paw elevation time.6
The first injection caused relatively short-lasting nociception (at least
up to 8 h), and 72 h later the paw elevation time response had fully
returned to those of control values. Following a second injection
72 h after the first, the nociceptive responses evoked by subsequent
inflammatory insults were significantly increased relative to those
evoked in a naive joint. However, we observed some differences in
our inflammatory model; that is, we did not find increased thermal
and mechanical hyperalgesia after the second and third inductions
of inflammation. This might be because of the difference in the
applied tests (paw elevation time vs gait analysis and PWD tests).
Alternatively, it might be because of the different routes of
administration (knee joint vs ankle joint).
A number of studies have reported that gait changes in the arthritic
rat can be used as an objective measure of pain and that temporal
and spatial changes in gait observed in inflammatory hyperalgesia
models might be owing to the avoidance of the normally non-
noxious mechanical stimulation induced by walking.19–21 Min et al.
recently described a novel method that allows convenient measure-
ment of the severity of arthritic pain in the knee joint in voluntarily
walking rats.10,22,23 Their results suggest that this is an effective tool
with which we can determine arthritic pain under dynamic condi-
tions. One of the advantages of their method is that the animals walk
voluntarily and, therefore, stress imposed on the animals during the
test is minimal. Furthermore, their method reflects painful states
more realistically because it measures the weight load while the rat
is walking. Accordingly, it determines primary hyperalgesia and it
seems more sensitive than the PWD test, which assesses secondary
thermal hyperalgesia. However, we have also detected some weak-
nesses in their model. We observed that the animals often stopped
Fig. 3 The curves indicate the relative weight load of the (a) hind paws and (b) fore paws of the control and diclofenac-treated animals. (), Control right;
(), control left; (), diclofenac right; and (), diclofenac left. *No significant difference when compared with the baseline value (i.e. the mechanical allodynia
is relieved) (P < 0.05). †Significant difference between control and diclofenac-treated animals (P < 0.05). #Significant difference compared with the baseline
value observed on Day 1 am on the non-inflamed side (P < 0.05). The arrows show the time points at which carrageenan was injected.
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in the corridor, making it difficult to determine the exact weight load
for all four legs. Moreover, in contrast to the results of Min et al., water
deprivation did not constitute a strong drive for the rats to walk to
the dark box. Hence, we applied a vanilla smell,24 which seemed more
appropriate. Our results revealed that the device might be an appro-
priate method for the long-lasting investigation of ankle joint pain.
The mechanisms of carrageenan-induced inflammation and sub-
sequent hyperalgesia have been studied extensively.25–27 The induction,
maintenance and spread of chronic hyperalgesia could result from
a series of peripheral and central changes occurring at the site of the
insult and at spinal or supraspinal sites. Cyclooxygenase inhibitors,
including diclofenac, are widely used therapeutic options in the treat-
ment of inflammatory disorders, but their long-term usage also causes
serious adverse effects, such as gastrointestinal haemorrhage.28 It has
been shown that oral treatment with 3 mg/kg diclofenac is effective
against inflammation in rats,7,8 and we therefore applied this dose
in our experiments. In the present study, we found that this dosage
exhibited different degrees of efficacy for the various parameters.
Thus, anti-oedemic effects appeared earlier than anti-allodynic effects,
whereas it did not influence secondary thermal hyperalgesia. The
anti-oedemic potency of NSAID is a well-known effect, which is
a result of the decrease in the level of prostaglandins.29
However, several others factors could cause pain, including
nerve growth factor, which is not affected directly by diclofenac.16
Thus, the increased rate of recovery of mechanical hyperalgesia
during diclofenac treatment suggests that the anti-inflammatory effect
of diclofenac caused a delayed decrease in mechanical pain. There
is another possibility for its varying potency in the tests. The cross-
sectional area indicates the enlargement of the joint and has a
positive direction but the behavioural tests, including the PWD and
the weight load tests, usually show that pain decreases. Consequently,
the test results have a negative direction and might be saturated, thus
this discrepancy may result from the saturation of pain behaviour.
So, the behavioural test can be used for observing the slope of recovery
from the maximal painful status. The slope of recovery seems to be
fairly constant after each injection, and clearly shows the significant
antihyperalgesic effect of diclofenac on mechanical hyperalgesia
after the third injection. As secondary thermal hyperalgesia indicates
central excitation, changes in the gait reflect mainly primary hyper-
algesia. Thus, we suggest that this dose of diclofenac (i.e. 3 mg/kg)
was not sufficient to influence central changes significantly.
In conclusion, we have presented a regional, limited form of
repeatedly induced arthritis for long-term studies of inflammation
and nociception without causing signs of a systemic disease. The
findings of the present study clearly demonstrate the development
of chronic hyperalgesia following repeated injections of carrageenan
into the ankle joint of rats. Furthermore, with the repetition of
carrageenan administration the time-course of the inflammation
could be well controlled. Our experimental paradigm may provide
a model that is suitable for the investigation of drugs or treatments
that express their effects several days after their application. The
advantage of this model is to extend the period of inflammation, and
we suggest that by increasing the number of carrageenan injections,
the inflammatory changes and the effects of treatment could be
followed for an even longer time. Our present findings cannot be
extrapolated directly to the clinical management of pain, but this
experimental model of repeated acute joint inflammation may be
a suitable model for painful joint disorders with recurrent flare-ups
in humans (e.g. rheumatoid arthritis).
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